Cytotoxic potentials of biologically fabricated platinum nanoparticles from Streptomyces sp. on MCF‐7 breast cancer cells

Abstract

Biosynthesis of novel therapeutic nano-scale materials for biomedical and pharmaceutical applications has been enormously developed, since last decade. Herein, the authors report an ecological way of synthesising the platinum nanoparticles (PtNPs) using sp. for the first time The produced PtNPs exhibited the face centred cubic system. The fourier transform infrared spectrum revealed the existence of amino acids in proteins which serves as an essential reductant for the formation of PtNPs. The spherical morphology of the PtNPs with an average size of 20-50 nm was observed from topographical images of atomic force microscopy and field emission scanning electron microscopy. The X-ray fluorescence spectrum confirms the presence of PtNPs with higher purity. The PtNPs size was further confirmed with transmission electron microscopy analysis and the particles were found to exist in the same size regime. Additionally, PtNPs showed the characteristic surface plasmon resonance peak at 262 nm. Dynamic light scattering studies report that 97.2% of particles were <100 nm, with an average particle diameter of about 45 nm. Furthermore, 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-tetrazolium assay based cytotoxicity analysis was conducted for the PtNPs, which showed the inhibitory concentration (IC) at 31.2 µg/ml against Michigan Cancer Foundation-7 breast cancer cells.

Bacteriogenic Platinum Nanoparticles for Application in Nanomedicine

“…IC 50 value was found to be 31.2 µg/mL. Anticancer property of bacteriogenic PtNPs was found to be dose-dependent (Baskaran et al, 2017).…”

“…UV-Vis spectra showed absorption peak at 262 nm indicating synthesis of PtNPs which were face centered cubic (FCC) of crystalline nature with size of 24.1 nm. Atomic force microscopy (AFM) and TEM analyses confirmed that the size of the bacteriogenic PtNPs were spherical with 20-50 nm size (Baskaran et al, 2017).…”

“…was attributed to the bacterial chloride reductase enzyme which is generally involved in nitric acid cycle and plays an important role in the reduction of chloride to chlorine. Nicotinamide adenine dinucleotide dependent chloride reductase enzyme might play a vital role in synthesis of PtNPs where the Pt ions were probably reduced via an electron shuttle enzymatic metal reduction process (Baskaran et al, 2017).…”

Usage of Platinum Nanoparticles for Anticancer Therapy over Last Decade: A Review

“…Synthesis of PtNPs of size range average size range 2.3 nm has been documented using platinum tetrachloride as precursor and sodium borohydride as reducing agent. [78] Use of ethylene glycol as reducing agent and solvent under sonication using precursor chloroplatinic acid and time bound Strong cytotoxic activity against cancer cells and proved to be an effective therapy for breast cancer therapy [126] Iron Platinum nanoparticles (FePt NPs) addition of surfactant polyvinyl pyrrolidone has been reported to regulate the size of PtNPs. [79] The advantage of chemical methods includes synthesis of size controlled, high yield, easy functionalization, cost effective, reduced dispersity and thermally stable PtNPs.…”

Stability analysis of platinum nanoparticles prepared by ESDM in deionised water

“…The current application of platinum includes conductive electrodes to increase their sensitivity to reactants [1][2][3][4], contact resistance and conductivity of individual platinum nanowires embedded in coplanar waveguide structures are investigated at high frequencies [5]. In terms of biomedical, platinum nanoparticle through biosynthesis was used as a therapeutic drug for breast cancer [6]. Platinum nanoparticle was used as a catalyst to enhance the antibacterial effect of silver nanoparticles [7].…”